bladder cancer
-
December 13, 2019
Plasmacytoid Urothelial Carcinoma: An Unusual Variant That Warrants Aggressive Management and Critical Distinction on Transurethral Resections Bookmark
George Lundberg, MDResearch paper from the Archives of Pathology & Laboratory Medicine curated by Editor in Chief George Lundberg, MD, who notes:
Plasmacytoid urothelial carcinoma merits special aggressive therapy.
Go to full paper published in the Archives of Pathology & Laboratory Medicine.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 13, 2019
Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients with Locally Advanced or Metastatic Urothelial Carcinoma After Platinum-Based Therapy (RANGE): Overall Survival and Updated Results of a Randomised, Double-Blind, Phase 3 Trial Bookmark
George Lundberg, MDResearch paper from The Lancet curated by Editor in Chief George Lundberg, MD, who notes:
A drug called Cyramza improves progession-free survival (PFS) but not overall survival (OS) of patients with advanced bladder cancer in a phase lll clinical trial.
Go to full paper published in The Lancet.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
August 15, 2019
Bladder Cancer—A Comprehensive Overview Bookmark
George Lundberg, MDCurated by Editor in Chief George Lundberg, MD, who notes:
Cancer of the urinary bladder is common, commonly recurs, and can be fatal. To learn more, read this up-to-date, comprehensive, unbiased, and balanced report from Medscape.